Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 2/20 | 0.35 |
| ▸ | TIPARP | Q7Z3E1 | 5/20 | 0.34 |
| ▸ | NPC1 | O15118 | 4/20 | 0.32 |
| ▸ | RAB9A | P51151 | 4/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | HTT | P42858 | 4/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.32 |
| ▸ | S1PR2 | O95136 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30101362 | 0.89 | NPC1 (0.34) | KAT2BTIPARPNPC1RAB9AALDH1A1 | |
| SCHEMBL26914895 | 0.89 | NPC1 (0.33) | TIPARPNPC1RAB9AALDH1A1HTT | |
| SCHEMBL26914899 | 0.89 | NPC1 (0.33) | TIPARPNPC1RAB9AALDH1A1HTT | |
| SCHEMBL21521226 | 0.86 | TIPARP (0.41) | TIPARPCYP2C9PARP1PARP14PARP16 | |
| SCHEMBL21520955 | 0.86 | TIPARP (0.41) | TIPARPCYP2C9PARP1PARP14PARP16 | |
| SCHEMBL21522414 | 0.85 | KAT2B (0.40) | KAT2BNPC1RAB9AALDH1A1HTT | |
| SCHEMBL21522415 | 0.85 | KAT2B (0.40) | KAT2BNPC1RAB9AALDH1A1HTT | |
| SCHEMBL29841952 | 0.80 | TIPARP (0.31) | TIPARPNPC1RAB9AALDH1A1CYP2C9 | |
| SCHEMBL24639959 | 0.79 | NPBWR1 (0.46) | ALDH1A1HTTSMN1; SMN2MAPTBRD4 | |
| SCHEMBL24640411 | 0.79 | NPBWR1 (0.46) | ALDH1A1HTTSMN1; SMN2MAPTBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4234551-A2 | PYRIDAZINONES AS PARP7 INHIBITORS | Ribon Therapeutics Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230192664-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2023-06-22 | — | — | US | disclosed |
| EP-3788040-B1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS INC (US) | 2023-04-12 | — | — | EP | disclosed |
| US-11014913-B2 | Pyridazinones as PARP7 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| EP-3788040-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | Ribon Therapeutics Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20210024502-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2021-01-28 | — | — | US | disclosed |
| US-10870641-B2 | Pyridazinones as PARP7 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| US-20200123134-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2020-04-23 | — | — | US | disclosed |
| US-10550105-B2 | Pyridazinones as PARP7 inhibitors | Ribon Therapeutics Inc. (US) | 2020-02-04 | — | — | US | disclosed |
| US-20190330194-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2019-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024502-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | KAT2B 1487/4885TIPARP 152/4885NPC1 4551/4885 |
| US-10550105-B2 | Pyridazinones as PARP7 inhibitors | PARP2, PARP1, PARP4 | KAT2B 1487/4885TIPARP 152/4885NPC1 4551/4885 |
| US-20190330194-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | KAT2B 1487/4885TIPARP 152/4885NPC1 4551/4885 |
| US-11014913-B2 | Pyridazinones as PARP7 inhibitors | PARP2, PARP1, PARP4 | KAT2B 1487/4885TIPARP 152/4885NPC1 4551/4885 |
| US-10870641-B2 | Pyridazinones as PARP7 inhibitors | PARP2, PARP1, PARP4 | KAT2B 1487/4885TIPARP 152/4885NPC1 4551/4885 |
| US-20230192664-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | KAT2B 1487/4885TIPARP 152/4885NPC1 4551/4885 |
| US-20200123134-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | KAT2B 1487/4885TIPARP 152/4885NPC1 4551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.